|
Is extra-corporal liver support with prometheus safe in patients with end-stage liver disease?
May 21, 2008Patients with end-stage liver disease would benefit from liver supportive liver therapy while waiting for stabilization of hepatic functions or to enable bridging to liver transplantation. Albumin dialysis improves patients' general condition, including cardiovascular and renal function as well as the degree of hepatic encephalopathy. Studies evaluating the hemodynamic alterations in stable patients with cirrhosis during extra-corporal intervention remain scarce, though such knowledge might evidently improve patient safety and perhaps lessen reluctance toward the early use of extra-corporal liver support.
The decision to use extra-corporal liver support in the treatment of patients with end-stage liver disease hinges on many factors, with safety considerations a major concern. The choice of treatment will depend on the risk of adverse events, and possible positive or negative hemodynamic influences between the available treatment modalities.
A research article to be published on April 7, 2008 in the World Journal of Gastroenterology addresses these issues. In this clinical study, the authors aimed to determine the hemodynamic profile of intervention with Prometheus™, using MARS™ and hemodialysis as control groups, in patients with end-stage liver disease. They found the Prometheus system does not aggravate the systemic hemodynamics. However, Prometheus therapy does not exert an equally beneficial influence on arterial pressure as seen during MARS treatment. It was concluded that an intervention using extra-corporal liver support with albumin-dialysis should not be withheld merely because of safety considerations in the future.
World Journal of Gastroenterology
World Journal of Gastroenterology
Liver Disease News and Current Liver Disease Events RSSFatty liver linked to increased risk of diabetic kidney disease
For patients with type 2 diabetes, a condition called non-alcoholic fatty liver disease (NAFLD) may be an important risk factor for diabetes-related chronic kidney disease (CKD), according to a study in the August Journal of the American Society of Nephrology (JASN).
Miracle leaves that may help protect against liver damage
Sea buckthorn (Hippophae rhamnoides) berries are well known for their cholesterol busting properties, but scientists in India say that its leaves are also rich in anti-oxidants and may help ward off liver disease, according to new research due to be published in the Society of Chemical Industry's (SCI) Journal of the Science of Food and Agriculture.
Risk threshold of daily alcohol intake and drinking duration in liver injury?
Alcoholic threshold effect rather than a dose-response effect on mortality from alcohol-related liver injury. Alcohol intake, rather than the type of alcoholic beverage, was more significant to liver injury.
Study concludes no racial disparities in long-term outcomes in recipients of liver transplants
New research published in the Journal of the American College of Surgeons shows long-term survival and liver rejection rates are equivalent for African-American liver transplant patients as compared with patients of other races.
Researchers Find New Treatment for Hepatitis C
Researchers at the OU Health Sciences Center have found a new use for an old drug. Their findings appear online Friday in the American Journal of Gastroenterology.
Common bacteria activating natural killer T cells may cause autoimmune liver disease
A bacteria commonly found in soil and water triggered autoimmune symptoms in mice similar to those found in an incurable liver disease called Primary Biliary Cirrhosis (PBC).
Anti-HBe may play a role in the progression of the disease of hepatitis B
Genotype D is found to be the only detected type in different clinical forms of HBV infections, including cirrhosis, among residents of southwestern Iran. A significant association between the presence of anti-HBe antibody and increasing ALT levels among either HBeAg-negative or HBeAg-positive individuals was also determined.
Study shows positive findings in treating patients with advanced hepatitis C
The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).
New Research Shows Benefits of Ultrasound Contrast Agents Outweigh Potential Risk to Heart Patients
ST. LOUIS - A Saint Louis University cardiologist called upon the U.S. Food and Drug Administration (FDA) on Monday to reconsider a strong warning it recently placed on a diagnostic tool, stating that the warning could prevent doctors from detecting life-threatening cardiac events.
Early-onset obesity in father linked to increased potential for liver disease in child
A history of early-onset paternal obesity increases the odds of elevated liver enzyme levels in offspring and points to the potential for a genetic link between obesity and liver disease, according to a study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
More Liver Disease News Articles
 | The Liver-Cleansing Diet by Sandra Cabot |
 | The Amazing Liver & Gallbladder Flush by Andreas Moritz |
 | Dr. Melissa Palmer's Guide To Hepatitis and Liver Disease by Melissa Palmer |
 | The Healthy Liver & Bowel Book by Sandra Cabot |
 | Alpha Lipoic Acid Breakthrough: The Superb Antioxidant That May Slow Aging, Repair Liver Damage, and Reduce the Risk of Cancer, Heart Disease, and Diabetes by Burt Berkson |
 | Herbs for Hepatitis C and the Liver (A Storey Medicinal Herb Guide) by Stephen Harrod Buhner |
 | GI/Liver Secrets: with STUDENT CONSULT Access by Peter McNally |
| Gastrointestinal and Liver Pathology: A Volume in the Foundations in Diagnostic Pathology Series (Foundations in Diagnostic Pathology) by Christine A. Iacobuzio-Donahue, Elizabeth A. Montgomery | |
 | The First Year: Cirrhosis: An Essential Guide for the Newly Diagnosed (First Year, The) by James L. Dickerson |
 | The Hepatitis C Handbook by Matthew Dolan |
| © 2008 BrightSurf.com |